Automated HER2 assesment in breast cancer
2015
Pathology Friesland, Leeuwarden, Netherlands
Validation of a fully automated "in situ" hybridisation procedure combined with an automated imaging system for HER2-targeted therapy. It was possible to assess HER2 over 328 samples of breast tumour patients and, when compared to previous manual methods, the method showed to have a consistent efficacy. This platform can facilitate the routine assessment of HER2 in breast cancer patients for clinical purposes.
Fully automated fluorescent in situ hybridization (FISH) staining and digital analysis of HER2 in breast cancer: a validation study
Elise MJ van der Logt
Added on: 07-29-2021
[1] https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0123201[2] https://data.jrc.ec.europa.eu/dataset/ffebe454-ed9a-47cf-8a33-8cf70c1b7d38